Synlett 2009(20): 3373-3377  
DOI: 10.1055/s-0029-1218364
LETTER
© Georg Thieme Verlag Stuttgart ˙ New York

Solid-Supported Synthesis of Artificial Phospholipids

Takumi Furuta*a, Hitoshi Onukib, Masayoshi Mochizukib, Mai Itob, Makoto Inaib, Toshiyuki Wakimotob, Toshiyuki Kan*b
a Institute for Chemical Research, Kyoto University, Uji, Kyoto 611-0011, Japan
Fax: +81(774)383197; e-Mail: furuta@fos.kuicr.kyoto-u.ac.jp;
b School of Pharmaceutical Sciences, University of Shizuoka and Global COE program, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan
Fax: +81(54)2645745; e-Mail: kant@u-shizuoka-ken.ac.jp;
Further Information

Publication History

Received 3 September 2009
Publication Date:
11 November 2009 (online)

Abstract

A concise solid-supported synthesis of artificial phospholipids was developed. Functionalized phospholipids were prepared by introduction of a head group onto a solid-supported phospholipid framework in good overall yield and purity.

    References and Notes

  • For a recent review on artificial phospholipids, see:
  • 1a Zumbuehl A. Chimia  2009,  63:  63 
  • For examples on lipid-membrane protein and lipid-lipid interactions, see:
  • 1b Prestwich GD. Acc. Chem. Res.  1996,  29:  503 
  • 1c Ogawa Y. Hahn W. Garnier P. Higashi N. Massotte D. Metz-Boutigue M.-H. Rousseau B. Kodaka M. Sunamoto J. Ourisson G. Nakatani Y. Chem. Eur. J.  2002,  8:  1843 
  • 1d Sugahara M. Uragami M. Regen SL. J. Am. Chem. Soc.  2003,  125:  13040 
  • 1e Gubbens J. Ruijter E. de Fays LEV. Damen JMA. de Kruijff B. Slijper M. Rijkers DTS. Liskamp RMJ. de Kroon AIPM. Chem. Biol.  2009,  16:  3 
  • For examples on membrane protein crystallization, see:
  • 1f Drakopoulou E. Tsivgoulis GM. Mukhopadhyay A. Brisson A. Tetrahedron Lett.  2000,  41:  4131 
  • 1g Thompson DH. Zhou M. Grey J. Kim H. Chem. Lett.  2007,  36:  956 
  • 2 For a recent review on polymerizable lipids, see: Cashion MP. Long TE. Acc. Chem. Res.  2009,  42:  1016 
  • 3a Frias JC. Williams KJ. Fisher EA. Fayad ZA.
    J. Am. Chem. Soc.  2004,  126:  16316 
  • 3b Lampkins AJ. O’Neil EJ. Smith BD. J. Org. Chem.  2008,  73:  6053 
  • 3c Huang Z. Jaafari MR. Szoka FC. Angew. Chem. Int. Ed.  2009,  48:  1 
  • 3d Linderoth L. Peters GH. Madsen R. Andresen TL. Angew. Chem. Int. Ed.  2009,  48:  1823 
  • 3e Mulder WJM. Strijker GJ. Van Tilborg GAF. Cormode DP. Fayad ZA. Nicolay K. Acc. Chem. Res.  2009,  42:  904 
  • 4 Furuta T. Sakai M. Hayashi H. Asakawa T. Kataoka F. Fujii S. Suzuki T. Suzuki Y. Tanaka K. Fishkin N. Nakanishi K. Chem. Commun.  2005,  4575 
  • 5 Furuta T. Mochizuki M. Ito M. Takahashi T. Suzuki T. Kan T. Org. Lett.  2008,  10:  4847 
  • To the best of our knowledge, only one example of a solid-phase synthesis of phosphatidylethanolamines has been reported. In this case, the amino moiety of the head group was tethered to the resin for immobilization, see:
  • 6a Tomoi M. Kimura Y. Tokuyama S. React. Polym.  1991,  15:  63 
  • 6b For solid-supported synthesis of phospholipid-like bioactive molecules, see: Sasaki S. Ehara T. Alam MR. Fujino Y. Harada N. Kimura J. Nakamura H. Maeda M. Bioorg. Med. Chem. Lett.  2001,  2581 
  • 7 The following conditions were unsuccessful: alkylation conditions with benzyl chloride in the presence of Cs2CO3; condensation with benzyl alcohol by DCC; and the mixed anhydride method with 2,4,6-triisopropylbenzenesulfonyl chloride in the presence of DMAP
  • p-Anisidine was added as a catalyst for oxime bond formation, see:
  • 8a Dirksen A. Hackeng TM. Dawson PE. Angew. Chem. Int. Ed.  2006,  45:  7581 
  • 8b Dirksen A. Dawson PE. Bioconjugate Chem.  2008,  19:  2543 
  • 10 Alfonta L. Zhang Z. Uryu S. Loo JA. Schultz PG.
    J. Am. Chem. Soc.  2003,  125:  14662 
  • 11a García-Echeverría C. Tetrahedron Lett.  1997,  38:  8933 
  • 11b Guillier F. Orain D. Bradley M. Chem. Rev.  2000,  100:  2091 
  • 11c Tumelty D. Cao K. Holmes CP. Org. Lett.  2001,  3:  83 
  • 12 Scalone M. Waldmeier P. Org. Process Res. Dev.  2003,  7:  418 
9

Experimental Procedure for 11c
Wang resin (80 mg, 1.2 mmol/g, 96 µmol) placed in a syringe reactor was solvated with CH2Cl2, and then CH2Cl2 was replaced with toluene. To the resin in toluene (1.0 mL), was added Ph3P (25 mg, 96 µmol) and 5 (20 mg, 24 mmol). The suspension was shaken for 1 h at r.t., then DIAD (50 µL, 96 µmol) was added, and the suspension was shaken for 3 h at r.t. The resin was washed with toluene (3 × 3.0 mL), DMF (3 × 3.0 mL), CH2Cl2 (3 × 3.0 mL), and MeOH (3 × 3.0 mL), and dried in vacuo to give the resin 6.
To the resin 6 in toluene (1.0 mL), was added MeNHNH2 (3.8 µL, 72 µmol). The suspension was shaken for 15 min at r.t., then the resin was washed with toluene (3 × 3.0 mL), DMF (3 × 3.0 mL), CH2Cl2 (3 × 3.0 mL), and MeOH (3 × 3.0 mL), and dried in vacuo to give a resin 8. This step was repeated twice to complete the deprotection.
To the resin 8 in CH2Cl2 (1.0 mL), was added a solution of 2,3,4-trihydroxybenzaldehyde (9c; 37 mg, 239 µmol) and p-anisidine (12 mg, 100 µmol). The suspension was shaken for 17 h at r.t., then the resin was washed with CH2Cl2 (3 × 3.0 mL), DMF (3 × 3.0 mL), CH2Cl2 (3 × 3.0 mL), and MeOH (3 × 3.0 mL), and dried in vacuo to give a resin 10c.
The resin 10c was treated with 1% TFA in CH2Cl2 (1.0 mL) for 30 min. The TFA solution was collected, the resin was washed with CH2Cl2 (3 × 3.0 mL), the washes were collected, and the combined solutions were dried in vacuo to give 11c (6.7 mg, 33% from 5).
Analytical Data of 11c: [α]D ²4 +6.4 (c 0.3, CHCl3); ¹H NMR (500 MHz, CDCl3): δ = 8.07 (s, 1 H), 6.62 (d, J = 8.6 Hz, 1 H), 6.50 (d, J = 8.6 Hz, 1 H), 5.30-5.20 (m, 1 H), 4.45-4.10 (m, 8 H), 2.40-2.20 (m, 4 H), 1.70-1.50 (m, 4 H), 1.40-1.10 (m, 48 H), 0.88 (t, J = 6.9 Hz, 6 H); ¹³C NMR (100 MHz, CDCl3): δ = 173.7, 173.4, 152.2, 147.0, 145.2, 131.4, 122.5, 109.3, 107.8, 72.8, 69.5, 66.6, 65.1, 61.9, 34.1, 34.0, 31.9, 29.70, 29.66, 29.5, 29.4, 29.3, 29.12, 29.07, 24.8, 22.7, 14.1; IR (neat): 3460, 2918, 2851, 1740 cm; MS-FAB:
m/z = 843 [M - H]-; HRMS-FAB: m/z [M - H]- calcd for C44H77O12NP: 842.5184; found: 842.5167.

13

Experimental Procedure for 11b: To Merrifield resin (3.6 g, 1.1 mmol/g, 4.0 mmol) in DMF (30 mL), were added 12 (2.0 g, 12 mmol), Cs2CO3 (3.8 g, 12 mmol), and NaI (588 mg, 3.9 mmol), and the mixture was stirred for 40 h at r.t. The resin was washed with DMF (3 × 15 mL), H2O (3 × 15 mL), DMF (3 × 15 mL), CH2Cl2 (3 × 15 mL), DMF (3 × 15 mL), EtOAc (3 × 15 mL), CH2Cl2 (3 × 15 mL), and MeOH (3 × 15 mL), and then dried in vacuo to give resin 13 (4.1 g, 4.0 mmol, quant.).
The resin 13 (109 mg, 1.1 mmol/g, 120 µmol) placed in a syringe reactor was solvated with CH2Cl2, and then CH2Cl2 was replaced with toluene. To the resin 13 in toluene (1.0 mL), were added Ph3P (25 mg, 96 µmol) and 5 (20 mg, 24 µmol). The suspension was shaken for 1 h then, DIAD (50 µL, 96 µmol) was added and the suspension was shaken for 3 h at r.t. The resin was washed with toluene (3 × 3.0 mL), DMF (3 × 3.0 mL), CH2Cl2 (3 × 3.0 mL), and MeOH (3 × 3.0 mL), and then dried in vacuo to give resin 14.
To the resin 14 in toluene (1.0 mL), was added MeNHNH2 (3.8 µL, 72 µmol). The mixture was shaken for 15 min, then the resin was washed with toluene (3 × 3.0 mL), DMF (3 × 3.0 mL), CH2Cl2 (3 × 3.0 mL), and MeOH (3 × 3.0 mL), and dried in vacuo to give resin 15. This step was repeated twice to complete the deprotection.
To the resin 15 in CH2Cl2 (1.0 mL), was added p-bromo-benzaldehyde (9b; 31 mg, 239 µmol) and p-anisidine (12 mg, 100 µmol). The suspension was shaken for 21 h at r.t., then the resin was washed with CH2Cl2 (3 × 3.0 mL), DMF (3 × 3.0 mL), CH2Cl2 (3 × 3.0 mL), and MeOH (3 × 3.0 mL), and dried in vacuo to give the resin 16. To the resultant resin 16 in CH2Cl2 (1.0 mL), was added mCPBA (29 mg, 167 µmol) and the mixture was shaken for 1 h at r.t., and then washed with CH2Cl2 (3 × 3.0 mL), DMF (3 × 3.0 mL), CH2Cl2 (3 × 3.0 mL), and MeOH (3 × 3.0 mL), and dried in vacuo to give the sulfone resin 17. After treatment of resin 17 with a solution of Et3N in CH2Cl2 (7%, 1.0 mL) for 16 h, the filtrate was collected and dried in vacuo to give 11b as a Et3N salt (11 mg). For desalting and purification, TFA (10 µL) was added to a solution of 11b˙Et3N salt in CHCl3-MeOH (4:1, 0.5 mL) then the solution was dried in vacuo to give a residue, which was purified by preparative TLC on silica gel (CHCl3-MeOH-TFA, 80:20:0.1) to give 11b (4.7 mg, 22% from 5).